Ronald Alan Peck, MD

Ron Peck, M.D., is a medical oncologist and biopharmaceutical leader with 30 years of experience in drug development, and founder and principal consultant of Veritas Oncology LLC. He was most recently Chief Medical Officer at Arvinas, overseeing development of its PROTAC degrader portfolio including vepdegestrant. At TESARO, he led Clinical Research, advancing niraparib and immuno-oncology agents including dostarlimab. He began his industry career at Bristol Myers Squibb, contributing to development of ipilimumab. Dr. Peck is an adjunct assistant professor at Yale, and was on faculty at the University of Virginia. He earned his M.D. from Thomas Jefferson University and completed residency and fellowship at Georgetown University.